BioArctic AB 2022 AR2
The report highlights BioArctic's historic 2022 financial year, marked by groundbreaking clinical progress and portfolio expansion. Most notably, the company's partner Eisai presented positive Phase 3 results for lecanemab, an Alzheimer's drug candidate that demonstrated a 27 percent reduction in clinical decline. BioArctic also expanded its research pipeline with new projects in Parkinson's disease, ALS, and Gaucher disease, incorporating its proprietary Brain Transporter technology to enhance drug delivery across the blood-brain barrier. Financially, the company strengthened its position, reporting net revenue of MSEK 228.3, largely driven by milestone payments from Eisai. Additionally, BioArctic continued to build its Nordic commercial organization to prepare for the potential launch of lecanemab.
Company: BioArctic AB
Sector: Professional & technical services
Country: Sweden
Year: 2022
Type: AR2
Pages: 128
Back to company
BioArctic AB
Annual Report
The report highlights BioArctic's historic 2022 financial year, marked by groundbreaking clinical progress and portfolio expansion. Most notably, the company's partner Eisai presented positive Phase 3 results for lecanemab, an Alzheimer's drug candidate that demonstrated a 27 percent reduction in clinical decline. BioArctic also expanded its research pipeline with new projects in Parkinson's disease, ALS, and Gaucher disease, incorporating its proprietary Brain Transporter technology to enhance drug delivery across the blood-brain barrier. Financially, the company strengthened its position, reporting net revenue of MSEK 228.3, largely driven by milestone payments from Eisai. Additionally, BioArctic continued to build its Nordic commercial organization to prepare for the potential launch of lecanemab.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2022
Reporting Period
Jan 1, 2022 - Dec 31, 2022
Fiscal Year
2022
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women on Board
Workplace Fatalities
Employees